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ABSTRACT
Objectives: There is some debate about the value received for the money
spent on prescription drugs. Some argue that most drug spending is on
“me-too” drugs—drugs that provide only marginal health gains. Others
suggest that the opposite is true—new drugs offer good value for money
and are well worth the cost. To provide evidence on this issue, we evalu-
ated the impact of drug innovation on the longevity of Canadians.
Methods: We analyzed patient-level claims data from Quebec’s provincial
health plan. We selected elderly patients with continuous health coverage
dispensed at least one drug prescription in each year of the study period,
1997 to 2006. Drug vintage was deﬁned as the active ingredient’s earliest
marketed date. We estimated the impact of drug vintage on patient sur-
vival using a time-varying Cox proportional hazards model that con-
trolled for year indicator variables, patient age, sex, region of residence,
low income status, medical services use, concomitant drug use, and
comorbidities.
Results: Of the 102,743 subjects in the study population, 14,154 (14%)
died during the study period. Mean patient age was 68 years; 59% were
women. Our survival models indicated that the use of newer medications
was associated with a statistically signiﬁcant mortality risk reduction
(hazard ratio: 0.522; 95% conﬁdence interval: 0.476 to 0.572,P < 0.0001),
relative to older medications. Other covariates associated with an increased
risk of mortality included age, sex (male), low guaranteed income supple-
ment status, hospitalization, and number of comorbidities.
Conclusion: This analysis showed that recent drug innovation has had a
signiﬁcant beneﬁcial impact on the longevity of elderly patients.
Keywords: Canada, drug innovation, longevity, pharmaceuticals, survival.
Introduction
There is some debate about the value received for the money
spent on prescription drugs. Most drug expenditure growth in
Canada is due to substitution of newer for older medications.
Some argue that most drug spending is on “me-too”
drugs—medications that provide only marginal health gains [1].
Canada’s Patented Medicine Prices Review Board classiﬁed 89%
of the new active substances introduced over the period 2001
to 2006 as offering only limited or no therapeutic advantages
over existing drugs [1]. Others suggest that the opposite is
true—spending on new drugs has contributed to the 11-year gain
in life expectancy in Canada during the last 50 years [2] and thus
represents good value for money [3,4]. For instance, recent inno-
vation in cancer therapy has had considerable impact, not only in
cancer care and survival, but also in quality of life improvement
for cancer patients [5–7]. Similar ﬁndings were also reported in
other disease areas, such as human immunodeﬁciency virus
(HIV) and cardiovascular disease (CVD). For instance, Lichten-
berg showed that new drugs played a key role in a sharp decline
in the number of US deaths caused by HIV from 1995 to 1998
[8,9]. With respect to CVD, Cutler et al. reported that the use of
new drugs to manage hypertension and hyperlipidemia and to
dissolve blood clots have markedly reduced CVD morbidity and
mortality [10]. More recently, it was estimated that average
blood pressures in the US for 1999 to 2000 would have been
10% to 13% higher without the use of antihypertensive drugs
[11]. The authors also reported that 86,000 excess premature
deaths from CVD would have occurred in 2001 if these drugs
were not on the market [11]. New treatments also have the
potential to reduce costly hospitalization admissions [12–14].
Some of the methods and particularly the aggregate nature of
the data used in the literature of drug innovation have been
criticized [15]. As far as we know, detailed individual-level data,
allowing to control for other determinants of patient health
outcomes and nondrug health-care costs that could be correlated
with the use of newer treatments, have not been used yet to
document potential gains from drug innovation in Canada.
Studies using individual patient-level survival data yield compel-
ling estimates of the impact of drug innovation on longevity
for several reasons. First, these data allow researchers to better
control for other determinants of longevity that might be corre-
lated with drug innovation, such as age, sex, medical resources
utilization, and comorbidities. Second, these data lend them-
selves to more precise measurement of drug consumption.
Finally, analyses of individual-level data are less liable to various
statistical problems, such as nonstationarity. The problem of
nonstationarity in aggregate time series occurs when there is no
long-run mean to which the longitudinal data returns. Because
the standard econometric theory is derived under the assumption
that variables of concern are stationary and the error term has
zero expected value, standard techniques are invalid in the pres-
ence of nonstationary data. The level of gross domestic product
is an example of nonstationary time series, as its mean value
constantly increases over time.
This study therefore used patient-level survival data to esti-
mate the impact of drug innovation on longevity. We modeled the
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survival of senior residents of the province of Quebec, from
several birth cohorts who were afﬂicted with a variety of health
problems. Survival hazards were modeled semiparametrically as
a function of the vintage of the prescription drugs used (follow-
ing Lichtenberg 2004) [16] as well as controls for a variety of
factors unique to the patient (age, sex, indicator of low income,
region of residence, disease status) and their use of other health
services (hospitalization and physicians services). Brieﬂy, we
found evidence that drug vintage has a marked effect on survival,
with newer drugs leading to increased longevity, especially for the
treatment of asthma and CVD.
Patients and Methods
Hazard Model
The impact of drug innovation on longevity, conditional on
time-varying patient demographic characteristics, use of medical
services, and the nature and complexity of disease was estimated
using a semiparametric hazard model. This technique models the
hazard or the instantaneous probability of dying at any point in
time among those who are still alive at that time. Such model
allowed us to handle censored observations and appropriately
model the dependent variable (survival), which is usually non-
normally distributed. Although there are no assumptions made
about the shape of the underlying hazard function, this approach
assumes a multiplicative relationship between the probability of
dying and the log-linear function of the covariates, also referred
to as the “proportionality” assumption. In practical terms, this
model assumes that given two observations with different values
for the covariates of interest, the ratio of the hazard functions for
those two observations does not depend on time.
Data Source
Medical and pharmacy claims data from Quebec’s provincial
health plan, Régie de l’assurance maladie du Québec (RAMQ),
from January 1997 to December 2006 were used in this analysis.
Data elements were drawn from four RAMQ databases: 1) Infor-
mation personne assurée, patient demographic characteristics; 2)
Périodes d’admissibilité, patient eligibility and type of coverage; 3)
Services pharmaceutiques, outpatient prescription drug dispens-
ing; and 4) Services médicaux, medical services billed. The four
RAMQ databases are linked via a unique and encrypted patient
identiﬁer and allow longitudinal follow-up of patients. Informa-
tion on the vintage of drug ingredients was drawn from theHealth
Canada Drug Product Database (available at: http://www.hc-
sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php).
Drug Vintage Deﬁnition
We elected to deﬁne drug vintage as the earliest date of sale
reported for each ingredient contained in the drug. Hence, if the
drug was a combination of ingredients (e.g., hydrochlorothiaz-
ide, a combination of angiotensin-converting enzyme inhibitor
and diuretic in the control of hypertension), each ingredient
contained in the drug was separately considered as a prescription
with its own drug vintage. The Health Canada Drug Product
Database contains the marketed date of each active ingredient
for each drug product. This marketed date is reported by phar-
maceutical companies (notiﬁcation is mandatory) to Health
Canada.
Following the approach proposed by Lichtenberg [16], we
generated the following drug vintage variables to assess the
impact of drug innovation in the analysis:
• Pre-1970: the proportion of a patient’s drug prescriptions
made of active ingredients dated before 1970;
• Post-1970: the proportion of a patient’s drug prescriptions
made of active ingredients dated after 1970;
• Post-1980: the proportion of a patient’s drug prescriptions
made of active ingredients dated after 1980;
• Post-1990: the proportion of a patient’s drug prescriptions
made of active ingredients dated after 1990.
The “Pre-1970” period was the reference category in the regres-
sion analysis. In this context, because we used a cumulative
distribution approach to formulate the drug vintage covariate, the
parameter estimate associated with the variable “Post-1970” may
be interpreted as the “marginal beneﬁt” associated with the
consumption of only 1970s versus Pre-1970 medications; the
coefﬁcient associated with the variable “Post-1980” may be inter-
preted as the “marginal beneﬁt” associated with the consumption
of only 1980s versus 1970s medications; and the coefﬁcient
associated with the variable “Post-1990” may be interpreted as
the “marginal beneﬁt” associated with the consumption of only
Post-1990 versus 1980s medications. The cumulative impact on
the hazard of dying of all Post-1970 medications relative to only
Pre-1970 ingredients can be determined by adding the three
coefﬁcients (i.e., bPost-1970 + bPost-1980 + bPost-1990).
Other Determinants of Survival
The other covariates used for adjustment in the regression model
were year indicator variables and patient-speciﬁc demographic
characteristics (age, sex, and region of residence), government
guaranteed income supplement (GIS) status (an indicator of low
income), medical resources utilization, drug utilization, and
comorbidities.
The variables controlling for medical services use were strati-
ﬁed by inpatient and outpatient services. For the inpatient
setting, we included two covariates in the model: a variable
indicating the number of inpatient admissions for each calendar
year and a variable indicating the total hospital length of stay
(days) during the calendar year. For the outpatient setting, we
controlled for the number of outpatient consultations to any
physician and for the occurrence of consultations to a specialist
(yes/no) during the calendar year. With respect to drug use, we
controlled for the number of pharmacy claims observed during
the calendar year, after adjusting the prescription length to 28
days per prescription.
Lastly, following the approach proposed by Lichtenberg [16],
we inserted two categorical covariates to control for the nature of
the person’s illnesses in our model. First, we used the Interna-
tional Classiﬁcation of Diseases, Ninth revision (ICD-9) diagno-
sis codes reported in all medical claims to calculate the fraction of
each person’s diagnoses (i.e., DISEASE_SHARE) that were in
each of the following broad disease categories: 1) Infectious and
parasitic diseases (ICD-9 codes: 001–139); 2) Neoplasms (ICD-9
codes: 140–239); 3) Endocrine, nutritional, metabolic, immunity
disorders (ICD-9 codes: 240–279); 4) Diseases of the blood and
blood-forming organs (ICD-9 codes: 280–289); 5) Mental disor-
ders (ICD-9 codes: 290–319); 6) Diseases of the nervous system
and sense organs (ICD-9 codes: 320–389); 7) Diseases of the
circulatory system (ICD-9 codes: 390–459); 8) Diseases of
the respiratory system (ICD-9 codes: 460–519); 9) Diseases of
the digestive system (ICD-9 codes: 520–579); 10) Diseases of the
genitourinary system (ICD-9 codes: 580–629); 11) Skin and sub-
cutaneous tissue disorders (ICD-9 codes: 680–709); 12) Muscu-
loskeletal system and connective tissue disorders (ICD-9 codes:
710–739); 13) Congenital anomalies (ICD-9 codes: 740–759);
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14) Conditions originating in the perinatal period (ICD-9 codes:
760–779); and 15) Symptoms, signs, and ill-deﬁned conditions
(ICD-9 codes: 780–799). For example, if all of person i’s diag-
noses were diabetes (ICD-9: 250), then DISEASE_SHAREij = 1 if
j = 3 and DISEASE_SHAREij = 0 if j  3. On the other hand, if
this person had three circulatory diagnoses and one digestive
diagnosis, then DISEASE_SHAREij = 0.75 if j = 7, DISEASE_
SHAREij = 0.25 if j = 9, and DISEASE_SHAREij = 0 otherwise.
Such covariate allowed us to estimate the differences in mortality
rates associated with these different diagnosis groups (i.e., allow-
ing relative comparisons across disease categories).
In addition to measuring the shares of diagnoses in each
disease category, we generated an index to determine the
person’s “effective number” of disease categories as follows:
N_DISEASE_CATEGORYi = 1/Sj DISEASE_SHAREij2
If all of a person’s diagnoses fell in one disease category, then
N_DISEASEi = 1. If half of a person’s diagnoses fell in one
disease category, and half fell in a second category, then
N_DISEASEi = 1/(0.52 + 0.52) = 2. If 90% of a person’s diag-
noses fell in one disease category, and 10% fell in a second
category, then N_DISEASEi = 1/(0.92 + 0.12) = 1.22.
Study Population
To be included in the analysis, patients were required to have
continuous health plan coverage, to be 65 years old, and to
have at least one drug prescription per calendar year. To preserve
representativeness throughout the study period, three different
birth cohorts, each of the same size, were randomly extracted
from the RAMQ database. The ﬁrst cohort included patients
who were 65 years or older as of 1997; the second included
patients who met the same criterion as of 1999; and the third
group met the age criterion as of 2001. Patients were considered
as continuously enrolled if there was no gap in their enrollment
exceeding 31 days.
In addition to estimating the model using data on the entire
population, we also estimated the model separately for three
subpopulations: 1) patients with asthma (ICD-9 code: 493); 2)
cancer patients (ICD-9 codes: 140–209); and 3) patients with
CVD (ICD-9 codes: 402, 404, 410–414, 425, 428–438, 440,
443–445). We selected these subpopulations in the design phase
of our study in light of the recent drug innovation observed
for those indications as well as the representativeness of those
three diseases in the overall population. To be considered in this
analysis, patients were required to have their ﬁrst diagnosis
of the corresponding condition during the ﬁrst two years of
observation.
Statistical Analysis
Estimating the impact of drug vintage on survival. Multivariate
analysis was conducted to adjust for potential confounding
factors in estimating the impact of drug vintage on patient’s
survival. The probability of death was analyzed using a time-
varying Cox proportional hazards model. In such a model, the
hazard of death, or the instantaneous probability that the event
will occur, is explicitly parameterized with individual character-
istics by using the information included in time-varying covari-
ates. The dependent variable “dead” is an indicator if the person
is alive (value 1) or not (value 0) at each speciﬁc year of the study.
The estimated coefﬁcients are interpreted as the impact on the
probability of being dead. A negative coefﬁcient means that an
increase in the corresponding variable is associated with longer
survival duration or lower probability of being dead. In the case
of a dummy variable, the parameter estimate measures the effect
on the survival time when the variable goes from zero to one
(i.e., changing the status for this variable) controlling for the
other covariates of the model. In the case of categorical variables,
the parameter estimates are to be interpreted as deviations from
the reference category. Finally, in the case of discrete variables,
the marginal effect is the impact of a one-unit increase on the
hazard of being dead.
Sensitivity Analysis
Sensitivity analyses using alternative regression models were also
performed to evaluate the robustness of the study ﬁndings. The
additional models we estimated included logistic regression mod-
eling the probability of being dead and structural accelerated
failure time models using various statistical distributions (e.g.,
Weibull, Gamma) to assess survival.
Furthermore, we tested the discriminative validity of our
model by running an antitest. Speciﬁcally, we focused on patients
with health conditions for which new medications likely offer
quality-of-life beneﬁts, but no survival beneﬁts. A ﬁnding that
there is no impact of drug vintage on longevity of such patients
provides evidence regarding the discriminative validity of our
model. We focused on patients with arthritis, mental disorders,
and skin problems.
All statistical analyses were performed using SAS release 9.1
or newer (SAS Institute, Inc., Cary, NC).
Results
Study Population Characteristics
The four different patient group dispositions and characteristics
are presented in Table 1. The overall population consisted of
102,743 subjects, of which 14,154 (14%) died during the study
period. The three other groups of interest were subpopulations
having higher percentages of death. Cancer patients had the
highest death rate (28%), followed by subjects with CVD (21%).
Mean age of the study population was 68 years, and region
and income status disposition were similar over the four groups.
The percentage of women differed in the CVD group, which
included more men (56%) than the other groups.
The level of health services utilization was highest in the
cancer group. The entire study population had an average of 14
outpatient consultations per year, 9 (64%) of which were with a
specialist. The entire population had 47 prescriptions per year on
average, which was smaller than the average in each of the three
speciﬁc disease groups. The patients suffered from 2.4 different
“effective” disease categories, on average, as previously deﬁned.
The disease breakdown showed that infectious and parasitic
diseases and circulatory system problems were the primary illness
categories.
Drug Vintage Statistics
Table 2a,b shows the most prescribed ingredients during the
study period. In Table 2a, the 10 most prescribed ingredients are
presented for each of the distinct drug vintage categories. The
2000 to 2006 category was combined with the 1990 to 1999
group for the multivariate analysis as their shorter observable
period (2000–2006) resulted in a limited use of these drugs (i.e.,
<3% of total dispensing; see Table 1).
It is worth noting that the ingredients presented in Table 2a
are also reported in the IMS Health Canada “Top 200 drugs
dispensed in Canada” publications from 2000 to 2006 [17].
Every year, IMS Health Canada publishes a list of the most
utilized drugs in Canada and approximately 70% of the ingre-
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dients listed in our Table 2a appear in the IMS Health Canada
publications under a generic or brand drug name. This suggests
that the patient proﬁle of users in this study is somewhat com-
parable to the Canadian population.
The top 20 prescribed ingredients are also presented for each
subpopulation of interest in Table 2b. The ingredients for asthma
and CVD reported in Table 2b are representative of the treat-
ments available on the market. Ingredients for the cancer
population are treatments used before and after a cancer for
prevention or to recover from side effects linked to chemo-
therapy. Unfortunately, chemotherapy agents administered in
the inpatient/hospital setting are not available from the RAMQ
database, which explains why commonly used regimens are not
reported in Table 2b for this subpopulation.
Survival Analysis
The Cox regression coefﬁcients and hazard ratios (HR) (i.e.,
hazard of dying) are presented in Table 3a. The results indicated
that women have longer survival duration, with an HR of 0.598
of dying compared with men. Patients with full to partial GIS
have a higher risk of dying than patients without GIS, suggesting
that patients with a higher income have a higher life expectancy.
Table 1 Study population characteristics
Overall population Asthma Cancer CVD
Study population disposition
Number of subjects 102,743 6,912 12,341 29,394
Observation period (year), mean (SD) 8.6 (2.2) 8.6 (2.3) 7.5 (3.0) 8.3 (2.5)
Mortality rate, n (%) 14,154 (14) 1,220 (18) 3,479 (28) 6,043 (21)
Cohort
1997, n (%) 36,269 (35) 2,503 (36) 4,759 (39) 11,238 (38)
1999, n (%) 33,784 (33) 2,315 (33) 3,879 (31) 9,660 (33)
2001, n (%) 32,690 (32) 2,094 (30) 3,703 (30) 8,496 (29)
Demographics
Age, mean (SD) 68 (1.7) 68 (1.7) 68 (1.8) 68 (1.7)
Female, n (%) 60,742 (59) 4,410 (64) 6,381 (52) 13,164 (44)
Region, n (%)
Montreal 24,791 (24) 1,883 (27) 3,138 (25) 7,089 (24)
Quebec 9,260 (9) 562 (8) 1,073 (9) 2,717 (9)
Mauricie 7,633 (7) 332 (5) 811 (7) 2,085 (7)
Monteregie 15,509 (15) 1,133 (16) 1,975 (16) 4,482 (15)
Other 40,493 (39) 2,647 (38) 4,672 (38) 11,352 (38)
Government GIS status, n (%)
Full GIS 3,265 (3) 208 (3) 385 (3) 785 (3)
Partial GIS 42,865 (42) 2,297 (33) 4,493 (36) 9,792 (33)
Without GIS 56,600 (55) 4,407 (64) 7,460 (60) 18,815 (64)
Yearly medical and drug utilization, mean (SD)
Inpatient hospitalization admission* 0.3 (0.6) 0.6 (1.1) 0.7 (1.4) 0.6 (1.1)
Inpatient length of stay, days 2.7 (6.71) 4.5 (9.4) 5.1 (10.8) 4.5 (8.9)
Outpatient consultation* 14 (10.39) 20 (12.4) 21 (14.3) 18 (13.7)
Specialist consultation 9 (8.90) 12 (10.6) 15 (13.2) 12 (12.6)
Drug utilization, prescription† 47 (29.16) 61 (37.4) 50 (31.8) 65 (34.7)
Drug vintage, % of medication use
Pre-1970 30 32 33 34
1970–1979 14 16 15 13
1980–1989 19 16 20 19
1990–1999 34 35 31 33
2000–2006 2 2 1 2
Comorbidities
Number of disease, mean (SD) 2.4 (0.9) 2.8 (0.9) 2.7 (0.9) 2.6 (0.9)
Number of disease category, %
0 5 2 2 2
1 22 14 16 19
2 31 28 30 31
3 23 27 25 25
4 13 18 16 14
5 7 12 10 9
Disease category‡, %
Infectious and parasitic diseases 66 78 74 71
Neoplasms 18 21 66 20
Endocrine, nutritional, metabolic, immunity 29 28 29 33
Mental disorders 15 19 17 15
Nervous system and sense organs 31 35 33 33
Circulatory system 51 55 53 79
Respiratory system 28 67 32 33
Digestive system 17 23 22 20
Genitourinary system 23 26 27 23
Skin and subcutaneous tissue 15 18 19 16
Musculoskeletal system and connective tissue 32 40 34 33
Symptoms, signs, and ill-deﬁned conditions, % 35 52 44 44
*Inpatient hospitalizations refer to any hospitalizations and emergency-room visits lasting more than 1 day. Outpatient consultations refer to any hospitalizations and emergency-room visits
lasting no more than 1 day, plus physician outpatient visits.
†Prescriptions were normalized to 28 days of therapy.
‡Reported as annual rates.
CVD, cardiovascular disease; GIS, guaranteed income supplement.
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Patients who have been hospitalized are more likely to die.
Each additional hospital admission per year is associated with a
16.4% increase in the risk of dying. Furthermore, patients with 1
to 5 “effective” diseases are 1.5 to 4.6 times more likely to die
compared with those in good health (i.e., no “effective” disease).
Similarly, patients requiring specialist consultation face an 18%
increase in the risk of dying relative to those patients without
specialist consultation during the year. As might be expected with
an elderly population, a diagnosis of cancer (neoplasm) signiﬁ-
cantly increased the risk of mortality. Interestingly, after control-
ling for the occurrence of specialist consultation, the number of
outpatient visits to any physician has an opposite impact on
hazard risk. Every consultation is associated with a 1% reduction
in the risk of dying, suggesting that a sustained follow-up by a
physician is beneﬁcial for elderly people to control and recover
their health. Such follow-up might also allow patients to have
access to appropriate medication and signiﬁcantly increases
survival time.
Table 2 (a) Most prescribed active ingredients, stratiﬁed by drug vintage
category. (b) Most prescribed active ingredients, stratiﬁed by disease group
(a)
Active ingredient
Drug
vintage
% of prescriptions
for the category
Drug vintage: Pre-1970
Acetylsalicylic acid Dec-10 17
Hydrochlorothiazide Dec-59 13
Levothyroxine sodium Dec-51 12
Conjugated estrogens Dec-51 8
Calcium Dec-51 5
Vitamin D3 Dec-51 4
Furosemide Dec-66 3
Medroxyprogesterone acetate Dec-60 3
Warfarin sodium Dec-57 3
Acetaminophen Dec-49 3
Drug vintage: 1970–1979
Lorazepam Dec-77 18
Metoprolol tartrate Dec-77 15
Glyburide Dec-71 14
Oxazepam Dec-72 8
Clonazepam Dec-77 6
Salbutamol Dec-72 6
Flurazepam hydrochloride Dec-71 4
Estradiol Dec-76 3
Timolol Dec-79 3
Propranolol hydrochloride Dec-74 2
Drug vintage: 1980–1989
Atenolol Dec-88 11
Diltiazem hydrochloride Dec-88 9
Nifedipine Dec-82 9
Omeprazole Dec-89 8
Enalapril maleate Dec-87 6
Indapamide Dec-82 6
Triamterene Dec-81 5
Acebutolol hydrochloride Dec-86 4
Ipratropium bromide Dec-83 4
Alprazolam Dec-81 3
Drug vintage: 1990–1999
Atorvastatin Mar-97 11
Metformin hydrochloride Dec-93 7
Amlodipine Dec-92 6
Simvastatin Dec-90 5
Ramipril Dec-93 4
Pravastatin sodium Dec-90 4
Alendronic acid Dec-96 3
Pantoprazole Mar-97 3
Irbesartan Jun-98 3
Lisinopril Dec-90 3
Drug vintage: 2000–2006
Esomeprazole Aug-01 21
Rosuvastatin Feb-03 19
Bisoprolol fumarate Jun-00 15
Rosiglitazone Mar-00 8
Tiotropium Nov-02 5
Alfuzosin hydrochloride Feb-02 4
Rabeprazole sodium Apr-02 4
Ezetimibe Jun-03 4
Pioglitazone Aug-00 3
Mirtazapine May-01 2
Table 2 Continued
(b)
Active ingredient
Drug
vintage
% of prescriptions
for the population
Asthma subpopulation
Fluticasone propionate Mar-93 4.1
Acetylsalicylic acid Dec-10 4.0
Levothyroxine sodium Dec-51 4.0
Hydrochlorothiazide Dec-59 3.4
Salbutamol Dec-72 3.2
Conjugated estrogens Dec-51 2.8
Atorvastatin Mar-97 2.8
Lorazepam Dec-77 2.2
Diltiazem hydrochloride Dec-88 2.0
Ipratropium bromide Dec-83 1.9
Salmeterol Dec-94 1.9
Omeprazole Dec-89 1.7
Amlodipine Dec-92 1.6
Metformin hydrochloride Dec-93 1.6
Calcium Dec-51 1.6
Furosemide Dec-66 1.4
Vitamin D3 Dec-51 1.4
Budesonide Dec-90 1.3
Pantoprazole Mar-97 1.2
Alendronic acid Dec-96 1.2
Cancer subpopulation
Levothyroxine sodium Dec-51 5.5
Acetylsalicylic acid Dec-10 4.8
Atorvastatin Mar-97 4.2
Hydrochlorothiazide Dec-59 3.7
Lorazepam Dec-77 2.4
Conjugated estrogens Dec-51 2.1
Metformin hydrochloride Dec-93 2.0
Amlodipine Dec-92 1.7
Omeprazole Dec-89 1.7
Pravastatin sodium Dec-90 1.7
Simvastatin Dec-90 1.6
Atenolol Dec-88 1.6
Alendronic acid Dec-96 1.6
Metoprolol tartrate Dec-77 1.6
Calcium Dec-51 1.6
Vitamin D3 Dec-51 1.5%
Diltiazem hydrochloride Dec-88 1.5
Nifedipine Dec-82 1.4
Glyburide Dec-71 1.3
Tamoxifen Dec-86 1.2
Cardiovascular disease subpopulation
Acetylsalicylic acid Dec-10 8
Atorvastatin Mar-97 6
Levothyroxine sodium Dec-51 3
Hydrochlorothiazide Dec-59 3
Diltiazem hydrochloride Dec-88 3
Metoprolol tartrate Dec-77 3
Simvastatin Dec-90 2
Atenolol Dec-88 2
Amlodipine Dec-92 2
Metformin hydrochloride Dec-93 2
Pravastatin sodium Dec-90 2
Lorazepam Dec-77 2
Furosemide Dec-66 2
Nitroglycerin Dec-64 2
Conjugated estrogens Dec-51 2
Warfarin sodium Dec-57 2
Ramipril Dec-93 2
Nifedipine Dec-82 2
Glyburide Dec-71 1
Omeprazole Dec-89 1
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Table 3 (a) Multivariate Cox regression model using time-varying covariates. (b) Multivariate Cox regression model using time-varying covariates—
adjusted impact of drug vintage on survival, stratiﬁed by disease group*
(a)
Variable
Parameter
estimate
Hazard
ratio (HR)
95% HR
conﬁdence limit P-value
Drug vintage
Pre-1970 (reference) — — — —
Post-1970 0.283 1.328 [1.213; 1.453] <0.0001
Post-1980 -0.349 0.706 [0.639; 0.779] <0.0001
Post-1990 -0.651 0.522 [0.476; 0.572] <0.0001
Demographics
Age 0.178 1.195 [1.182; 1.209] <0.0001
Female -0.514 0.598 [0.576; 0.620] <0.0001
Year dummies
1997 (reference) — — — —
1998 -0.168 0.846 [0.704; 1.015] 0.0725
1999 0.364 1.439 [1.219; 1.699] <0.0001
2000 0.019 1.019 [0.858; 1.210] 0.8275
2001 0.377 1.458 [1.234; 1.722] <0.0001
2002 0.337 1.400 [1.180; 1.662] 0.0001
2003 0.187 1.205 [1.008; 1.441] 0.0401
2004 0.101 1.106 [0.921; 1.328] 0.2816
2005 -0.054 0.947 [0.784; 1.145] 0.5741
2006 -0.318 0.728 [0.597; 0.888] 0.0017
Government GIS status
Full GIS 0.216 1.241 [1.129; 1.364] <0.0001
Partial GIS 0.012 1.012 [0.974; 1.051] 0.5371
Without GIS (reference) — — — —
Region
Montreal -0.038 0.963 [0.921; 1.005] 0.0860
Quebec 0.028 1.029 [0.965; 1.096] 0.3872
Mauricie -0.355 0.701 [0.649; 0.757] <0.0001
Monteregie 0.021 1.021 [0.971; 1.074] 0.4122
Other (reference) — — — —
Yearly medical resources utilization
Inpatient hospitalization frequency 0.151 1.164 [1.156; 1.171] <0.0001
Inpatient length of stay 0.017 1.017 [1.017; 1.018] <0.0001
Outpatient consultation frequency -0.008 0.992 [0.990; 0.993] <0.0001
Specialist consultation (yes/no) 0.168 1.183 [1.104; 1.267] <0.0001
Number of prescription -0.016 0.984 [0.983; 0.985] <0.0001
Comorbidities
Number of disease category
No disease (reference) — — — —
1 disease 0.406 1.501 [1.137; 1.981] 0.0041
2 diseases 0.797 2.218 [1.683; 2.923] <0.0001
3 diseases 1.106 3.021 [2.291; 3.983] <0.0001
4 diseases 1.400 4.056 [3.072; 5.354] <0.0001
5 diseases 1.537 4.653 [3.518; 6.154] <0.0001
Disease category
Infectious and parasitic diseases -3.011 0.049 [0.035; 0.069] <0.0001
Neoplasms 2.210 9.113 [7.035; 11.806] <0.0001
Endocrine, nutritional, metabolic, immunity -1.573 0.207 [0.156; 0.276] <0.0001
Mental disorders -1.005 0.366 [0.273; 0.490] <0.0001
Nervous system and sense organs -2.816 0.060 [0.044; 0.081] <0.0001
Circulatory system -0.419 0.658 [0.506; 0.854] 0.0017
Respiratory system 0.177 1.194 [0.912; 1.563] 0.1974
Digestive system -1.089 0.337 [0.248; 0.457] <0.0001
Genitourinary system 1.546 4.694 [3.526; 6.250] <0.0001
Musculoskeletal system and connective tissue -0.242 0.785 [0.583; 1.057] 0.1110
Symptoms, signs, and ill-deﬁned conditions 3.677 39.528 [30.735; 50.837] <0.0001
Regression information
Likelihood ratio: <0.0001
Number of patient-year observations: 859,858
Total number of events: 13,084
(b)
Overall population (N = 102,743)
Pre-1970 (reference) — — — —
Post-1970 0.283 1.328 [1.213; 1.453] <0.0001
Post-1980 -0.349 0.706 [0.639; 0.779] <0.0001
Post-1990 -0.651 0.522 [0.476; 0.572] <0.0001
Post-1970 vs. pre-1970 -0.717 0.488
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Demographic characteristics, GIS status, region, medical
and drug resources utilization, and comorbidity results
from asthma, cancer, and CVD sub-analyses had similar
impacts on survival time (results not shown here; available
upon request).
Impact of Drug Vintage on Survival
The results of the impact of drug vintage on patients’ probability
of survival are reported in Table 3b. For each population, the
Pre-1970 period was the reference category in the regression
model. The results of this analysis consistently indicated that the
use of Post-1990 ingredients signiﬁcantly reduced the risk of
mortality. These ﬁndings suggest that recent drug innovation, in
particular Post-1990 medications, had a signiﬁcant beneﬁcial
impact on the survival of patients.
When the cumulative impact of newer drugs on the
hazard of dying (i.e., bPost-1970 + bPost-1980 + bPost-1990: Post-1970
vs. Pre-1970 medications) was calculated, the results indicated
that the introduction of the new treatments in the last three
decades reduced the risk of mortality by 51% for the overall
population (HR: 0.488 for Post-1970 medication relative to
Pre-1970). This ﬁnding was even stronger for the subpopula-
tion analyses (asthma: HR = 0.286; cancer: HR = 0.420; CVD:
HR = 0.327).
To illustrate the impact of drug vintage on mortality, we
plotted the survival curves based on the estimated drug vintage
regression coefﬁcients (evaluated at the sample means for the
other covariates), assuming that a patient would consume only 1)
Post-1990; 2) 1980 to 1989; 3) 1970 to 1979; and 4) Pre-1970
medications. Figure 1 clearly demonstrates that recent drugs (i.e.,
marketed after 1990) had a substantial contribution to improv-
ing patients’ survival. The results for the CVD subpopulation
(Fig. 1d) highlight how drug innovation has constantly and
markedly reduced mortality in this speciﬁc disease group popu-
lation. The estimated 10-year mortality rate according to vintage
category steadily declined between the Pre-1970 and the Post-
1990 categories, dropping from 16.8% to 5.8%, respectively.
Sensitivity Analysis
The results of the sensitivity analyses using alternative regression
models corroborated the study conclusion (results not shown
here; available upon request). The logistic model for the overall
population indicated that the utilization of Post-1990 ingredients
was associated with a 49% (95% conﬁdence interval: 43–54%)
reduction in the risk of mortality, as compared with older ingre-
dients. Based on the structural accelerated failure time models,
the results revealed that the use of recent drugs was consistently
associated with a statistically signiﬁcant increase in longevity
using various statistical distributions (Weibull, Gamma, and
log-logistic).
Finally, the anti-test results provided further evidence of the
discriminative validity of our model (Fig. 2). As expected, the
ﬁndings from the model based on patients with arthritis, mental
disorder, or skin problems indicated no appreciable survival bene-
ﬁt for recent medications (i.e., no drug vintage impact), as com-
paredwith the overall population and the subpopulations (Fig. 1).
These results suggest that our model accurately predicts the
survival impact of drug vintage, as demonstrated by these condi-
tions where medications may be intended to improve patients’
quality of life and are not expected to yield longevity gains.
Discussion
In his article on the effect of drug vintage on survival, Lichten-
berg reported that the Puerto Rico Health Insurance Administra-
tion (ASES) beneﬁciaries using new ingredients were less likely
to die [16]. The estimated mortality rates from Pre-1970 to
Post-1990 decreased from 4.4% to 2.5%, respectively.
The present study investigated drug vintage impact on
the survival time of elderly RAMQ beneﬁciaries. In contrast
to Lichtenberg’s methodology, a Cox regression model using
time-varying covariates was used for the analysis. Using medical
and pharmacy claims from the RAMQ database, drug vintage,
which was measured using the Health Canada database, showed
a positive and signiﬁcant impact on survival time, with only one
exception, the Post-1970 vintage category (i.e., drugs introduced
between 1970 and 1979). Mortality rates (similar to ASES ben-
eﬁciaries) found for Pre-1970, 1970 to 1980, 1980 to 1989, and
Post-1990 drug vintage categories were 7.6%, 9.9%, 7.1%, and
3.8%, respectively.
In addition to estimating the model using data on the entire
population, we also examined three speciﬁc disease groups
(asthma, cancer, and CVD). Models estimated using data on
asthmatics showed important survival beneﬁts for 1970 to 1979
Table 3 Continued
Asthma subpopulation (n = 6,912)
Pre-1970 (reference) — — — —
Post-1970 -0.395 0.674 [0.470; 0.966] 0.0318
Post-1980 0.225 1.252 [0.837; 1.873] 0.2735
Post-1990 -1.082 0.339 [0.236; 0.486] <0.0001
Post-1970 vs. Pre-1970 -1.252 0.286
Cancer subpopulation (n = 12,341)
Pre-1970 (reference) — — — —
Post-1970 0.246 1.279 [1.080; 1.515] 0.0044
Post-1980 -0.359 0.699 [0.584; 0.836] <0.0001
Post-1990 -0.754 0.471 [0.393; 0.564] <0.0001
Post-1970 vs. Pre-1970 -0.867 0.420
CVD subpopulation (n = 29,394)
Pre-1970 (reference) — — — —
Post-1970 -0.021 0.979 [0.833; 1.151] 0.8010
Post-1980 -0.488 0.614 [0.514; 0.733] <0.0001
Post-1990 -0.610 0.543 [0.462; 0.638] <0.0001
Post-1970 vs. Pre-1970 -1.119 0.327
*The drug vintage coefﬁcient estimates presented in this table were generated from the same regression model as reported inTable 3a, controlling for year indicator variables and patient-speciﬁc
age, sex, region of residence, low income status, medical services use, concomitant drug use, and comorbidities.
CVD, cardiovascular disease; GIS, guaranteed income supplement
Impact of Drug Vintage on Patient Survival 853
and Post-1990 ingredients. Interestingly, these two periods
coincide with periods of major innovations in asthma treatment
[18,19]. During the 1970s, short-acting b2-adrenergic receptor
agonists used for the relief of bronchospasm were improved. For
instance, salbutamol (Ventolin, GlaxoSmithKline, London, UK)
was introduced in 1972. This drug is similar to epinephrine
(adrenaline), but without all its side effects [20]. During the
following two decades, research focused essentially on preven-
tion instead of control or symptom reduction. There was no
signiﬁcant innovation in the 1980s, with the sole exception of
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ipratropium bromide (Atrovent, Boehringer Ingelheim, Ingel-
heim, Germany). The second major innovation in this therapeu-
tic area happened in the 1990s [20], when inhaled corticosteroids
and corticosteroid pills were launched.
The cancer subpopulation rendered similar results as the
overall population model. One important reason that could
explain the mitigated results for the drugs marketed between
1970 and 1990 is the fact that many effective chemotherapy
treatments administered to cancer patients are given in the
inpatient/hospital setting. Such information regarding treatments
administered to patients at the hospital is not available
in the RAMQ database. Our data cover primarily preventive and
recovery drugs, which are prescribed in an outpatient setting. To
illustrate this issue, only one chemotherapy treatment was
reported among the top ingredients prescribed to cancer patients
in our sample (tamoxifen for breast cancer treatment). Conse-
quently, our model was unable to precisely measure the beneﬁts
of recent chemotherapy agents in this population, which most
likely resulted in conservative estimates of the impact of drug
vintage on survival. Nevertheless, some speciﬁc ingredients can
be administered for prevention or health stabilization after che-
motherapy treatments, but that may not be the primary reason
for their dispensing. For example, metformin hydrochloride is
one of the primary recent (Post-1990) antidiabetic drugs used in
the treatment of diabetes mellitus type 2 that has been shown to
prevent colon or breast cancer in patients with diabetes [21,22].
With respect to CVD, the understanding of heart disease
and associated cardiac outcomes has evolved over the last
century. A better understanding of CVD problems has allowed
researchers to focus on prevention to stabilize cardiac outcomes
[23]. In the early 1970s, studies showed for the ﬁrst time a link
between hypertension and heart problems. Even though scien-
tists were aware of this association, it took time for traditional
treatments to be modiﬁed. Furthermore, it was only as recently
as the early 1990s that new research on treating elderly patients
for blood pressure showed that prevention for CVD complica-
tions is even more effective for elderly patients than for younger
ones [24]. In addition, a number of clinical trials have high-
lighted a positive correlation between cholesterol reduction and
a reduction in coronary heart disease risk; cholesterol-lowering
drugs (statins) were introduced during the 1990s [25]. Our
model reﬂects the reduction of mortality rate attributable to
these drug innovations.
Although claims data are a rich source of information on
health care and drug utilization, there are some inherent limita-
tions. Pharmacy-claims data do not provide any information on
patients’ compliance. Also, claims data are subject to coding
errors making it difﬁcult to identify underlying health problems
and disease severity. In estimating our model, however, we
attempted to control for patients’ illnesses by including many
covariates that are correlated with the disease severity. Despite
our attempt to control for all confounding factors, it is possible
that other important determinants such as the “quality of pre-
scriber” and the level of education also inﬂuenced the relation-
ship between drug innovation and survival. For example, it could
be argued that more skilled physicians prescribe newer drugs and
patients treated by such skilled physicians live longer. Even
though we tried to eliminate this potential bias by controlling for
the occurrence of specialist consultation or not, there might be
residual effects that the model is not capturing. Unfortunately,
education, type of work, environmental, and lifestyle (drinker,
smoker status, etc.) variables that are also important determi-
nants of health status were not available in the database. It is
also possible that patients taking newer medications are likely to
be more health conscious, thus living longer than those taking
older medications (creating endogeniety bias). Nevertheless, it is
important that, if this were true (i.e., healthier patients using
newer drugs or better physicians prescribing newer drugs), we
would ﬁnd that newer medications are always better; however,
we found that the survival beneﬁts varied with the period
of introduction for the asthma subpopulation, suggesting that
endogeniety bias might be negligible. Furthermore, the substan-
tial innovations made in surgery over the past three decades
that have greatly contributed to patients’ health status, thus life
expectancy, might be positively correlated with drug vintage. It
is unclear whether this is indeed the case; however, if patients
taking newer medications are more likely to have surgery, the
impact of drug innovation may be overestimated. Nevertheless, it
should be noted that these limitations are present in any study
conducted with claims data and are not speciﬁc to the present
study. Lastly, it is important to mention that the current study did
not address the policy implication, that is, by assessing the value
received for the money spent on newer prescription drugs. We
intend to address this question in future research.
Despite these limitations, our study had the advantage of
relying on patient-level information in estimating the impact of
drug vintage on patients’ survival. The complete claims history
allowed for adjustment of important confounding factors that
may otherwise bias the estimated impact of drug innovation. Our
study population was based on relatively healthy seniors from
Quebec, rendering a high generalizability of the study results.
Conclusion
The results of this analysis provide strong support for the
hypothesis that recent drug innovation, in particular medications
launched after 1990, had a signiﬁcant beneﬁcial impact on the
survival of elderly Canadians. Our model also accurately pre-
dicted the reduction of the mortality rate attributable to newer
agents used in the treatment of asthma and CVD.
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